SCHEMBL19867331

SCHEMBL19867331

COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1nc(Nc2ccccc2P(=O)(C(C)C)C(C)C)c2sccc2n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 12/20 0.75
INSR P06213 8/20 0.60
IGF1R P08069 8/20 0.60
AURKA O14965 2/20 0.60
ROS1 P08922 2/20 0.60
EML4 Q9HC35 2/20 0.60
PLK1 P53350 6/20 0.52
PTK2 Q05397 2/20 0.52
EGFR P00533 3/20 0.51
CHEK1 O14757 1/20 0.51
NUAK1 O60285 1/20 0.51
JAK2 O60674 1/20 0.51
STK10 O94804 1/20 0.51
PRKD3 O94806 1/20 0.51
SLC34A2 O95436 1/20 0.51
CHEK2 O96017 1/20 0.51
ABL1 P00519 1/20 0.51
CD74 P04233 1/20 0.51
ERBB2 P04626 1/20 0.51
LCK P06239 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22170300 0.92 ALK (0.74) ALKINSRIGF1RAURKAROS1
SCHEMBL19867374 0.92 ALK (0.73) ALKINSRIGF1RAURKAROS1
SCHEMBL19867319 0.91 ALK (0.71) ALKINSRIGF1RAURKAROS1
SCHEMBL19867387 0.91 ALK (0.61) ALKINSRIGF1RAURKAROS1
SCHEMBL19867330 0.90 ALK (0.65) ALKINSRIGF1RAURKAROS1
SCHEMBL19867187 0.90 ALK (0.61) ALKINSRIGF1RAURKAROS1
SCHEMBL21099563 0.86 ALK (0.74) ALKINSRIGF1RAURKAROS1
SCHEMBL19867265 0.86 ALK (1.00) ALKINSRIGF1RAURKAROS1
SCHEMBL21099499 0.85 ALK (0.75) ALKINSRIGF1RAURKAROS1
SCHEMBL21099624 0.84 ALK (0.73) ALKINSRIGF1RAURKAROS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof Hongyun Biotech Co., Ltd. (CN) 2021-08-03 US disclosed
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2019-07-11 US disclosed
WO-2018028721-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS 厦门大学 2018-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF ALK, MET, TIE1 ALK 1/4885INSR 2213/4885IGF1R 975/4885
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof ALK, MET, TIE1 ALK 1/4885INSR 2213/4885IGF1R 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.